MCID: GNR004
MIFTS: 51

Generalized Anxiety Disorder malady

Categories: Mental diseases

Aliases & Classifications for Generalized Anxiety Disorder

Aliases & Descriptions for Generalized Anxiety Disorder:

Name: Generalized Anxiety Disorder 12 52 14 69
Anxiety Generalized 52

Classifications:



External Ids:

Disease Ontology 12 DOID:14320
ICD10 33 F41.1
ICD9CM 35 300.02
NCIt 47 C92622
UMLS 69 C0270549

Summaries for Generalized Anxiety Disorder

Disease Ontology : 12 An anxiety disorder that is characterized by long-lasting anxiety that is not focused on any one object or situation.

MalaCards based summary : Generalized Anxiety Disorder, also known as anxiety generalized, is related to antisocial personality disorder and hypoglycemia. An important gene associated with Generalized Anxiety Disorder is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Circadian rythm related genes and cAMP signaling pathway. The drugs Alprazolam and Valproic Acid have been mentioned in the context of this disorder. Affiliated tissues include heart, amygdala and brain, and related phenotypes are Decreased viability and behavior/neurological

Wikipedia : 71 Generalized anxiety disorder (GAD) is an anxiety disorder characterized by excessive, uncontrollable and... more...

Related Diseases for Generalized Anxiety Disorder

Diseases related to Generalized Anxiety Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 111)
id Related Disease Score Top Affiliating Genes
1 antisocial personality disorder 29.9 HTR1A HTR2A
2 hypoglycemia 29.5 BDNF DRD2 SLC6A4
3 personality disorder 29.3 BDNF DRD2 HTR1A HTR2A MAOA SLC6A2
4 schizophrenia 28.6 BDNF DRD2 HTR1A HTR2A HTR3A MAOA
5 anxiety disorder 11.5
6 panic disorder 10.4
7 polyneuropathy 10.2 HTR1A HTR2A
8 nephronophthisis 13 10.2 HTR2A SLC6A4
9 aryepiglottic fold cancer 10.2 HTR1A HTR2A
10 social phobia 10.2
11 dry eye syndrome 10.2 HTR1A HTR2A SLC6A4
12 obsessive-compulsive disorder 10.2
13 neurogenic bladder 10.2 HTR2A MAOA SLC6A4
14 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 10.1 BDNF HTR2A SLC6A4
15 conjunctival pigmentation 10.1 MAOA SLC6A4
16 tinea pedis 10.1 HTR1A MAOA SLC6A4
17 autism spectrum disorder 10.1 BDNF SLC6A2 SLC6A4
18 splenic abscess 10.1 DRD2 HTR2A SLC6A4
19 anodontia 10.1 HTR1A HTR3A SLC6A4
20 abnormal pupillary function 10.1 HTR1A HTR3A
21 euthyroid sick syndrome 10.1 DRD2 HTR2A SLC6A4
22 agoraphobia 10.1
23 teratoma with malignant transformation 10.1 BDNF DRD2 HTR2A
24 primary angle-closure glaucoma 10.1 BDNF HTR1A HTR2A SLC6A4
25 mandibular cancer 10.1 HTR1A HTR3A SLC6A4
26 thalassemia 10.1 BDNF HTR1A TSPO
27 apperceptive agnosia 10.1 DRD2 HTR1A SLC6A4
28 intrahepatic gall duct cancer 10.1 BDNF HTR2A MAOA SLC6A4
29 allergic hypersensitivity disease 10.1 DRD2 HTR1A HTR2A
30 cholesteatoma 10.1 BDNF DRD2 SLC6A4
31 intracranial cavernous angioma 10.1 DRD2 SLC6A4
32 vascular cancer 10.1 DRD2 HTR1A HTR2A
33 epithelioid type angiomyolipoma 10.1 BDNF HTR2A SLC6A2 SLC6A4
34 kidney pelvis papillary carcinoma 10.1 HTR1A MAOA SLC6A2 SLC6A4
35 strongyloidiasis 10.1 DRD2 MAOA SLC6A4
36 alopecia 10.1 BDNF DRD2 SLC6A4
37 lichen disease 10.0 HTR1A HTR2A MAOA SLC6A4
38 chronic eosinophilic pneumonia 10.0 BDNF HTR1A MAOA SLC6A4
39 chorea gravidarum 10.0 DRD2 HTR1A
40 chagas disease 10.0 BDNF HTR2A HTR3A SLC6A4
41 waardenburg's syndrome 10.0 DRD2 HTR1A HTR2A SLC6A4
42 alzheimer disease 17 10.0 HTR1A HTR2A SLC6A4 TPH1
43 pyromania 10.0 DRD2 HTR2A MAOA SLC6A4
44 colorectal adenocarcinoma 10.0 DRD2 MAOA SLC6A2 SLC6A4
45 siberian tick typhus 10.0 BDNF HTR1A HTR3A TSPO
46 mucinous adenocarcinoma 10.0 BDNF DRD2 MAOA SLC6A4
47 hypereosinophilic syndrome 10.0 BDNF DRD2 MAOA SLC6A4
48 mixed lacrimal gland cancer 9.9 HTR1A HTR3A
49 nephrogenic adenoma of the urethra 9.9 DRD2 HTR3A SLC6A2 SLC6A4
50 ornithosis 9.9 DRD2 HTR3A MAOA SLC6A4

Comorbidity relations with Generalized Anxiety Disorder via Phenotypic Disease Network (PDN): (show all 18)


Acute Cystitis Anxiety Disorder
Bronchitis Chronic Myocardial Ischemia
Dependent Personality Disorder Dysthymic Disorder
Esophagitis Histrionic Personality Disorder
Hypertension, Essential Hypochondriasis
Hypothyroidism Irritable Bowel Syndrome
Obsessive-Compulsive Disorder Obsessive-Compulsive Personality Disorder
Osteoporosis Personality Disorder
Schizophreniform Disorder Somatization Disorder

Graphical network of the top 20 diseases related to Generalized Anxiety Disorder:



Diseases related to Generalized Anxiety Disorder

Symptoms & Phenotypes for Generalized Anxiety Disorder

GenomeRNAi Phenotypes related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.1 SLC6A4 HTR1A HTR3A
2 Decreased viability GR00381-A-3 9.1 SLC6A4 HTR1A HTR3A

MGI Mouse Phenotypes related to Generalized Anxiety Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 HTR2A HTR3A MAOA RGS2 SLC6A2 SLC6A4
2 cardiovascular system MP:0005385 10.02 CRHR1 DRD2 HTR1A MAOA RGS2 SLC6A2
3 homeostasis/metabolism MP:0005376 9.96 DRD2 HTR1A HTR3A MAOA SLC6A2 SLC6A4
4 endocrine/exocrine gland MP:0005379 9.87 BDNF CRHR1 DRD2 HTR2A HTR3A SLC6A4
5 integument MP:0010771 9.63 BDNF DRD2 HTR3A SLC6A2 SLC6A4 TPH1
6 muscle MP:0005369 9.43 DRD2 HTR2A HTR3A RGS2 SLC6A4 TPH1
7 nervous system MP:0003631 9.28 BDNF CRHR1 DRD2 HTR1A HTR3A MAOA

Drugs & Therapeutics for Generalized Anxiety Disorder

Drugs for Generalized Anxiety Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 985)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 28981-97-7 2118
2
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 99-66-1 3121
3
Glatiramer Acetate Approved, Investigational Phase 4 147245-92-9 3081884
4
Interferon beta-1b Approved Phase 4,Phase 2,Phase 3 145155-23-3
5
Epinephrine Approved, Vet_approved Phase 4,Phase 1,Phase 2 51-43-4 5816
6
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1 54-11-5 942 89594
7
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
8
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2078-54-8 4943
9
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
10
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2 27203-92-5 33741
11
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
12
Etomidate Approved Phase 4,Phase 2 33125-97-2 36339 667484
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 437-38-7 3345
14
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 137-58-6 3676
15
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59467-70-8 4192
16
Rocuronium Approved Phase 4,Phase 3 119302-91-9, 143558-00-3 441290
17
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 2 298-46-4 2554
18
Coal tar Approved Phase 4,Phase 1 8007-45-2
19
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
20
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 132539-06-1 4585
21
Oxcarbazepine Approved Phase 4,Phase 3 28721-07-5 34312
22
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
23
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59729-33-8 2771
24
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-23-7 5754 657311
25
Fexofenadine Approved Phase 4,Phase 1 83799-24-0 3348
26
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 60142-96-3 3446
27
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 75614-87-8, 51-45-6 774
28
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 148553-50-8 5486971
29
Diazepam Approved, Illicit, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 439-14-5 3016
30
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
31
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
32
Remifentanil Approved Phase 4 132875-61-7 60815
33
Sufentanil Approved, Investigational Phase 4,Phase 2 56030-54-7 41693
34
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
35
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 6740-88-1 3821
36
Acamprosate Approved, Investigational Phase 4,Phase 3,Phase 2 77337-76-9 71158
37
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
38
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2 16590-41-3 5360515
39
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
40
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54910-89-3 3386
41
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2 84057-84-1 3878
42
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3 113-45-1 4158
43
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
44
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1 79617-96-2 68617
45
Topiramate Approved Phase 4,Phase 3 97240-79-4 5284627
46
Tranylcypromine Approved Phase 4,Phase 3 155-09-9 441233
47
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
48
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 28523-86-6 5206
49
Capsaicin Approved Phase 4,Phase 3 404-86-4 1548943
50
Mannitol Approved, Investigational Phase 4,Phase 2 69-65-8 453 6251

Interventional clinical trials:

(show top 50) (show all 3270)
id Name Status NCT ID Phase
1 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder Unknown status NCT00662259 Phase 4
2 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD Unknown status NCT00579280 Phase 4
3 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status NCT00176592 Phase 4
4 Sodium Bicarbonate in Cardiopulmonary Resuscitation Unknown status NCT01377337 Phase 4
5 Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors Unknown status NCT00802919 Phase 4
6 Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol in Anxious Patients Unknown status NCT00355693 Phase 4
7 Effect of Music Over the Tolerance to Colonoscopy. Unknown status NCT01285284 Phase 4
8 The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms Unknown status NCT00866866 Phase 4
9 Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Unknown status NCT01517711 Phase 4
10 Study of the Safety and Efficacy of Botox in Bruxism Unknown status NCT00908050 Phase 4
11 Effect of Pre-injection of Lidocaine on Myoclonus Induced by Induction With Etomidate in Elderly Patients During General Anesthesia Unknown status NCT02141737 Phase 4
12 Interest of Intravaginal Electro-stimulation at Home by GYNEFFIK® Compared to Usual Care in Incontinent Patients With Prior Perineal Reeducation Unknown status NCT02029027 Phase 4
13 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4
14 Treatment Youth With Obsessive-Compulsive Disorder Unknown status NCT00708240 Phase 4
15 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4
16 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4
17 Effects of Etomidate on Postoperative Circadian Rhythm Changes of Salivary Cortisol in Children Unknown status NCT02013986 Phase 4
18 Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified(OL Study) Unknown status NCT02287259 Phase 4
19 Oral Midazolam for Sedation in Esophagogastroduodenoscopy(EGD) Unknown status NCT01990937 Phase 4
20 Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause Unknown status NCT01116310 Phase 4
21 Pregabalin for the Treatment of Uremic Pruritus Unknown status NCT01852318 Phase 4
22 Prevention of Posttraumatic Stress Disorder (PTSD) With Diazepam Unknown status NCT01221883 Phase 4
23 Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients Unknown status NCT02134093 Phase 4
24 Nurse Administered Propofol Sedation vs. Midazolam With Fentanyl-sedation for Flexible Bronchoscopy: A Randomized, Single Blind, Controlled Study of Satisfaction and Safety. Unknown status NCT02226328 Phase 4
25 Intramuscular Dexmedetomidine as Premedication Unknown status NCT01937611 Phase 4
26 Optimal Multimodal Analgesia in Laparoscopic Cholecystectomy Unknown status NCT00209885 Phase 4
27 Trial for the Treatment of Alcohol Dependence Unknown status NCT00120601 Phase 4
28 Optimal Multimodal Analgesia in Abdominal Hysterectomy Unknown status NCT00209872 Phase 4
29 Juvenile Bipolar Disorder Outpatient Program Unknown status NCT01000402 Phase 4
30 Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain Unknown status NCT01479556 Phase 4
31 Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx) Unknown status NCT02286063 Phase 4
32 Tranylcypromine Treatment of Bipolar Depression Unknown status NCT01430455 Phase 4
33 Topiramate in the Treatment of Pathological Gambling Unknown status NCT00245583 Phase 4
34 Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome Unknown status NCT02424695 Phase 4
35 Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia Unknown status NCT02040883 Phase 4
36 Effect of Midazolam on Inflammatory Response and Organ Function in Mechanically Ventilated Sepsis Patients With Different Immune Status Unknown status NCT02135055 Phase 4
37 Propofol Versus Midazolam as Premedication for Preterm Neonates With Respiratory Distress Syndrome (RDS) Unknown status NCT00797160 Phase 4
38 Effects of Different Doses of Dexmedetomidine on Postoperative Cognitive Dysfunction in Elderly Hypertensive Patients Unknown status NCT02224443 Phase 4
39 Trial Comparing Sedation for Endoscopy With Propofol Versus Midazolam in Cirrhotics Unknown status NCT01356121 Phase 4
40 Safety and Efficacy of Combined Sedation With Midazolam and Dexmedetomidine in ICU Patients Unknown status NCT02080169 Phase 4
41 The Effect of High-dose Remifentanil on Established Capsaicin-induced Hyperalgesia in Human Volunteers Unknown status NCT00886106 Phase 4
42 The Effect of Remifentanil on Established Capsaicin-Induced Hyperalgesia in Human Volunteers Unknown status NCT00789386 Phase 4
43 A Comparison of Propofol Versus Midazolam to Sedate Critically Brain Injury; Measurement of Cytokine Response and Assessment of Function Unknown status NCT01712477 Phase 4
44 A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury Unknown status NCT02071407 Phase 4
45 The Effect of High-dose Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers (HighDose RemiSun) Unknown status NCT01015482 Phase 4
46 The Effect of Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers Unknown status NCT00811837 Phase 4
47 Preventing Pain After Heart Surgery Unknown status NCT01480765 Phase 4
48 CYP3A4 Metabolism Before and After Surgery Induced Weight Loss Using Midazolam as Model Drug Unknown status NCT01519726 Phase 4
49 Buccal Midazolam Versus Nasal or Oral Midazolam Sedation for Minor Invasive Procedures in Children Unknown status NCT02408302 Phase 4
50 Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability Unknown status NCT02078336 Phase 4

Search NIH Clinical Center for Generalized Anxiety Disorder

Genetic Tests for Generalized Anxiety Disorder

Anatomical Context for Generalized Anxiety Disorder

MalaCards organs/tissues related to Generalized Anxiety Disorder:

39
Heart, Amygdala, Brain, Cortex, Prefrontal Cortex, Testes, Temporal Lobe

Publications for Generalized Anxiety Disorder

Articles related to Generalized Anxiety Disorder:

(show top 50) (show all 665)
id Title Authors Year
1
Predictors of remission from generalized anxiety disorder and major depressive disorder. ( 27863710 )
2017
2
Reduction in Costs after Treating Comorbid Panic Disorder with Agoraphobia and Generalized Anxiety Disorder. ( 28418834 )
2017
3
Long noncoding RNAs: New evidence for overlapped pathogenesis between major depressive disorder and generalized anxiety disorder. ( 28529365 )
2017
4
Combining Metacognitive Strategies with Traditional Cognitive Behavior Therapy in Generalized Anxiety Disorder: A Case Illustration. ( 28515551 )
2017
5
Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis. ( 28483071 )
2017
6
Repetitive transcranial magnetic stimulation of the right dorsal lateral prefrontal cortex in the treatment of generalized anxiety disorder: A randomized, double-blind sham controlled clinical trial. ( 28533148 )
2017
7
Client Retrospective Accounts of Corrective Experiences in Motivational Interviewing Integrated With Cognitive Behavioral Therapy for Generalized Anxiety Disorder. ( 28072459 )
2017
8
Long noncoding RNA as an indicator differentiating schizophrenia from major depressive disorder and generalized anxiety disorder in nonpsychiatric hospital. ( 28092449 )
2017
9
Prefrontal and amygdala engagement during emotional reactivity and regulation in generalized anxiety disorder. ( 28501740 )
2017
10
Childhood adversity, adult stress, and the risk of major depression or generalized anxiety disorder in US soldiers: a test of the stress sensitization hypothesis. ( 28443533 )
2017
11
Resting state functional connectivity in primary insomnia, generalized anxiety disorder and controls. ( 28500965 )
2017
12
Resting-state functional connectivity in generalized anxiety disorder and social anxiety disorder: Evidence for a dimensional approach. ( 28478685 )
2017
13
Generalized Anxiety Disorder, worry and attention to threat: A systematic review. ( 28448826 )
2017
14
Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder. ( 28075650 )
2017
15
The Association between Generalized Anxiety Disorder, Subthreshold Anxiety Symptoms and Fear of Falling among Older Adults: Preliminary Results from a Pilot Study. ( 28452660 )
2017
16
Impact of Comorbid Depressive Disorders on Subjective and Physiological Responses to Emotion in Generalized Anxiety Disorder. ( 27660375 )
2016
17
Working memory dysfunction associated with brain functional deficits and cellular metabolic changes in patients with generalized anxiety disorder. ( 27442922 )
2016
18
The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis. ( 27143896 )
2016
19
Diminished autonomic neurocardiac function in patients with generalized anxiety disorder. ( 27994467 )
2016
20
Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone. ( 27486544 )
2016
21
Associations between compulsive buying and substance dependence/abuse, major depressive episodes, and generalized anxiety disorder among men and women. ( 27215919 )
2016
22
Cortical inhibitory and excitatory function in drug-naive generalized anxiety disorder. ( 28040450 )
2016
23
Responsive Management of Early Resistance in Cognitive-Behavioral Therapy for Generalized Anxiety Disorder. ( 27031326 )
2016
24
An Underlying Common Factor, Influenced by Genetics and Unique Environment, Explains the Covariation Between Major Depressive Disorder, Generalized Anxiety Disorder, and Burnout: A Swedish Twin Study. ( 27620693 )
2016
25
Improvements in emotion regulation following repetitive transcranial magnetic stimulation for generalized anxiety disorder. ( 27467027 )
2016
26
A BRIEF ECOLOGICAL MOMENTARY INTERVENTION FOR GENERALIZED ANXIETY DISORDER: A RANDOMIZED CONTROLLED TRIAL OF THE WORRY OUTCOME JOURNAL. ( 27062682 )
2016
27
Major depressive disorder and generalized anxiety disorder show different autonomic dysregulations revealed by heart rate variability analysis in first onset drug-naA^ve patients without comorbidity. ( 27987241 )
2016
28
Psychometric evaluation of the Generalized Anxiety Disorder Screener GAD-7, based on a large German general population sample. ( 28088111 )
2016
29
Insomnia Symptoms Following Treatment for Comorbid Panic Disorder With Agoraphobia and Generalized Anxiety Disorder. ( 27019339 )
2016
30
Short-term open-label chamomile (Matricaria chamomilla L.) therapy of moderate to severe generalized anxiety disorder. ( 27912871 )
2016
31
Promising effects of treatment with flotation-REST (restricted environmental stimulation technique) as an intervention for generalized anxiety disorder (GAD): a randomized controlled pilot trial. ( 27016217 )
2016
32
Prediction Error Representation in Individuals With Generalized Anxiety Disorder During Passive Avoidance. ( 27631963 )
2016
33
Impaired Retrieval Inhibition of Threat Material in Generalized Anxiety Disorder. ( 27042388 )
2016
34
Examination of the Intolerance of Uncertainty Construct in Youth With Generalized Anxiety Disorder. ( 27654145 )
2016
35
Heart rate variability and generalized anxiety disorder during laboratory-induced worry and aversive imagery. ( 27449553 )
2016
36
New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. ( 27050932 )
2016
37
Generalized Anxiety Disorder and Hypoglycemia Symptoms Improved with Diet Modification. ( 27493821 )
2016
38
Developmental risk factors in generalized anxiety disorder and panic disorder. ( 27466747 )
2016
39
Generalized Anxiety Disorder and Social Anxiety Disorder, but Not Panic Anxiety Disorder, Are Associated with Higher Sensitivity to Learning from Negative Feedback: Behavioral and Computational Investigation. ( 27445719 )
2016
40
Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. ( 27643884 )
2016
41
Threshold and subthreshold Generalized Anxiety Disorder (GAD) and suicide ideation. ( 27849314 )
2016
42
Aberrant regional neural fluctuations and functional connectivity in generalized anxiety disorder revealed by resting-state functional magnetic resonance imaging. ( 27163197 )
2016
43
Integrating Motivational Interviewing With Cognitive-Behavioral Therapy for Severe Generalized Anxiety Disorder: An Allegiance-Controlled Randomized Clinical Trial. ( 26985729 )
2016
44
Relative effects of cognitive and behavioral therapies on generalized anxiety disorder, social anxiety disorder and panic disorder: A meta-analysis. ( 27637075 )
2016
45
Mental Stress-Induced Myocardial Ischemia Related to Generalized Anxiety Disorder in a Patient With Acute Coronary Syndrome and Normal Coronary Arteries. ( 27607164 )
2016
46
Acute Swedish Massage Monotherapy Successfully Remediates Symptoms of Generalized Anxiety Disorder: A Proof-of-Concept, Randomized Controlled Study. ( 27464321 )
2016
47
Are Major Depression and Generalized Anxiety Disorder Associated With Oligohydramnios in Pregnant Women? A Case-Control Study. ( 27357862 )
2016
48
Prevalence of Insomnia and Associated Factors in Outpatients with Generalized Anxiety Disorder Treated in Psychiatric Clinics. ( 27167699 )
2016
49
Study of Life Events and Personality Dimensions in Generalized Anxiety Disorder. ( 27190927 )
2016
50
Rapid detection of generalized anxiety disorder and major depression in epilepsy: Validation of the GAD-7 as a complementary tool to the NDDI-E in a French sample. ( 26994447 )
2016

Variations for Generalized Anxiety Disorder

Expression for Generalized Anxiety Disorder

Search GEO for disease gene expression data for Generalized Anxiety Disorder.

Pathways for Generalized Anxiety Disorder

Pathways related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
2
Show member pathways
11.94 BDNF DRD2 HTR1A
3 11.71 BDNF HTR1A HTR2A HTR3A MAOA SLC6A4
4 11.69 HTR1A HTR2A HTR3A MAOA SLC6A4 TPH1
5
Show member pathways
11.61 BDNF DRD2 MAOA
6
Show member pathways
11.56 DRD2 HTR1A HTR2A
7
Show member pathways
11.07 MAOA SLC6A2 SLC6A4
8
Show member pathways
10.86 MAOA SLC6A4
9
Show member pathways
10.75 MAOA TPH1
10 10.55 HTR1A HTR2A HTR3A MAOA SLC6A4 TPH1

GO Terms for Generalized Anxiety Disorder

Cellular components related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.43 CRHR1 DRD2 HTR1A HTR2A SLC6A2 SLC6A4
2 neuron projection GO:0043005 8.92 RGS2 SLC6A2 SLC6A4 TPH1

Biological processes related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 release of sequestered calcium ion into cytosol GO:0051209 9.57 DRD2 HTR2A
2 negative regulation of insulin secretion GO:0046676 9.56 DRD2 PSMD9
3 response to axon injury GO:0048678 9.55 DRD2 TSPO
4 regulation of dopamine secretion GO:0014059 9.54 DRD2 HTR2A
5 temperature homeostasis GO:0001659 9.52 DRD2 HTR2A
6 behavioral response to cocaine GO:0048148 9.51 DRD2 HTR2A
7 response to pain GO:0048265 9.49 SLC6A2 TSPO
8 vasoconstriction GO:0042310 9.48 HTR1A SLC6A4
9 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.46 DRD2 HTR2A
10 negative regulation of voltage-gated calcium channel activity GO:1901386 9.43 CRHR1 DRD2
11 behavior GO:0007610 9.4 HTR1A HTR2A
12 regulation of behavior GO:0050795 9.37 HTR1A HTR2A
13 response to drug GO:0042493 9.35 DRD2 HTR2A SLC6A2 SLC6A4 TSPO
14 monoamine transport GO:0015844 9.32 SLC6A2 SLC6A4
15 regulation of hormone secretion GO:0046883 9.26 HTR1A HTR2A
16 dopamine uptake involved in synaptic transmission GO:0051583 9.16 SLC6A2 SLC6A4
17 serotonin receptor signaling pathway GO:0007210 8.8 HTR1A HTR2A HTR3A

Molecular functions related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 beta-tubulin binding GO:0048487 9.4 RGS2 SLC6A2
2 neurotransmitter receptor activity GO:0030594 9.37 HTR1A HTR2A
3 G-protein alpha-subunit binding GO:0001965 9.32 HTR2A RGS2
4 monoamine transmembrane transporter activity GO:0008504 9.26 SLC6A2 SLC6A4
5 dopamine:sodium symporter activity GO:0005330 9.16 SLC6A2 SLC6A4
6 G-protein coupled serotonin receptor activity GO:0004993 9.13 HTR1A HTR2A HTR3A
7 serotonin binding GO:0051378 8.8 HTR1A HTR2A HTR3A

Sources for Generalized Anxiety Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....